Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

rent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue $112 $84 $715 $187

Operating expenses:

Research and development 13,449 15,754 54,780 56,995

General and administrative 6,364 5,974 20,458 16,634

Total operating expenses 19,813 21,728 75,2
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... , ... a vital role in Merrimack,s acquisition of Hermes Biosciences and partnership with sanofi-aventis ... Cambridge, MA (PRWEB) ... the discovery and development of novel treatments for cancer and inflammation, today announced that ...
... ... Look , ... 5, 2010 -- HealthTalker , the leader in word of mouth (WOM) marketing campaigns ... Massachusetts headquarters. HealthTalker also reported strong revenue and significant year-over-year growth for its third ...
... on a single atom oflet,s saygold to detach it from ... measure of the astonishing progress in nanotechnology that questions that ... being asked by engineers. To help with the answers, a ... (NIST) has built an ultra-stable instrument for tugging on chains ...
Cached Biology Technology:Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance 2HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry 2HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry 3NIST researchers holding steady in an atomic-scale tug-of-war 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... - (Toronto) A new study from the Centre for ... a variation of a specific gene may play a role ... of Alzheimer,s cases. This innovative study has combined genetics and ... developing late-onset Alzheimer,s disease long before symptoms appear. The ...
... examine the response to noise of a diverse range of ... found that many families of crustaceans previously assumed to be ... Lizard Island on the Great Barrier Reef, the team collected ... webs. On each of 34 nights, one light trap ...
... (Minority Access to Research Careers) Program has announced the ... Sports Medicine (ACSM) Southeast Chapter Annual Meeting in Greenville, ... to promote the entry of underrepresented minority students, postdoctorates ... community and to encourage the participation of young scientists ...
Cached Biology News:Combining brain imaging, genetic analysis may help identify people at early risk of Alzheimer's 2Rowdy residents warn crustaceans away from perilous reefs 2
Recombinant Human HGF...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: